Author

Zexiang Han

University of CambridgeORCID 0000-0002-8968-0860Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:protein structure· 2 Research Focus:drug response / drug discovery· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

Tuomas P. J. KnowlesiD· 3 shared Alessia SantambrogioiD· 1 shared Andreas EversiD· 1 shared Daoyuan QianiD· 1 shared Giuseppe LicariiD· 1 shared Katherine M. StottiD· 1 shared Michele VendruscoloiD· 1 shared Nadia A. ErkampiD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiophysics

Tuomas P. J. KnowlesORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Charge-driven remodelling of monomeric Tau determines its phase behaviour

Yudisthira Oktaviandie, Zexiang Han, Katherine M. Stott, Tuomas P. J. Knowles

This study shows that charge-driven conformational changes in Tau affect its phase behaviour and aggregation propensity.

bioRxiv · Sep 24, 2026 · PreprintBiophysics

Complex coacervation reshapes the aggregation landscape of tau

Zexiang Han, Pu Xu, Yangteng Ou, Daoyuan Qian, Zhenting Xiao, Yuxiang Wu, Alessia Santambrogio, Michele Vendruscolo, Tuomas P. J. Knowles

This study shows that complex coacervation changes tau aggregation by redirecting it to a distinct kinetic regime and altering amyloid properties.

bioRxiv · Jul 1, 2026 · PreprintBiophysics

Molecularly specific solubilization of therapeutic antibodies

Zexiang Han, Nadia A. Erkamp, Rob M. Scrutton, Giuseppe Licari, Olga Predeina, Andreas Evers, Pietro Sormanni, Tuomas P. J. Knowles

The paper quantifies how different excipients affect the solubility of therapeutic antibodies using a high-throughput platform and identifies molecular-specific and nonspecific interactions.

bioRxiv · Jan 30, 2026 · PreprintBiophysics